Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Crossref DOI link: https://doi.org/10.1186/s12962-018-0089-8
Published Online: 2018-01-30
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zafari, Zafar
,
Sadatsafavi, Mohsen
Mark FitzGerald, J.
Article History
Received: 24 January 2017
Accepted: 22 January 2018
First Online: 30 January 2018